Medpace's (MEDP) "Market Perform" Rating Reiterated at William Blair

William Blair restated their market perform rating on shares of Medpace (NASDAQ:MEDP - Free Report) in a report issued on Tuesday morning, MarketBeat Ratings reports. William Blair also issued estimates for Medpace's Q2 2025 earnings at $3.02 EPS, Q3 2025 earnings at $2.95 EPS, Q4 2025 earnings at $2.80 EPS, FY2025 earnings at $12.45 EPS, Q1 2026 earnings at $3.17 EPS, Q2 2026 earnings at $3.12 EPS, Q3 2026 earnings at $3.11 EPS, Q4 2026 earnings at $3.05 EPS and FY2026 earnings at $12.45 EPS.

A number of other research firms have also recently issued reports on MEDP. Leerink Partners assumed coverage on shares of Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price target for the company. Truist Financial reduced their target price on Medpace from $347.00 to $333.00 and set a "hold" rating for the company in a research note on Thursday, April 10th. Leerink Partnrs raised Medpace to a "hold" rating in a research report on Monday, March 24th. Mizuho cut their price objective on Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Finally, TD Cowen downgraded Medpace from a "buy" rating to a "hold" rating and decreased their target price for the stock from $370.00 to $328.00 in a report on Monday, April 14th. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $349.30.

Medpace Stock Down 1.4 %

Shares of Medpace stock traded down $4.33 during trading on Tuesday, reaching $298.55. The company's stock had a trading volume of 399,606 shares, compared to its average volume of 339,939. The company has a 50-day simple moving average of $313.79 and a two-hundred day simple moving average of $331.70. Medpace has a 1-year low of $250.05 and a 1-year high of $459.77. The company has a market cap of $9.02 billion, a price-to-earnings ratio of 23.64, a P/E/G ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The business had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same quarter in the previous year, the firm earned $3.20 earnings per share. As a group, analysts anticipate that Medpace will post 12.29 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Barclays PLC grew its stake in shares of Medpace by 71.9% during the 3rd quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after purchasing an additional 8,275 shares during the period. Virtu Financial LLC purchased a new stake in Medpace during the third quarter worth $1,503,000. Wilmington Savings Fund Society FSB acquired a new stake in Medpace during the third quarter valued at $175,000. Tidal Investments LLC increased its holdings in Medpace by 257.9% in the third quarter. Tidal Investments LLC now owns 3,654 shares of the company's stock valued at $1,220,000 after buying an additional 2,633 shares in the last quarter. Finally, Franklin Resources Inc. increased its holdings in Medpace by 19.4% in the third quarter. Franklin Resources Inc. now owns 188,141 shares of the company's stock valued at $66,508,000 after buying an additional 30,530 shares in the last quarter. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.